Why Belite Bio’s Stock Is Soaring: A Rare Disease Breakthrough

San Diego, Saturday, 13 June 2026.
Belite Bio’s stock surged after its experimental drug for Stargardt disease—a rare, incurable eye disorder—showed promising trial results. With no approved treatments and 53,000 U.S. patients, the therapy could dominate a $262 billion orphan drug market. The FDA’s rolling submission for approval marks a critical milestone, fueling investor confidence in the company’s potential to deliver the first-ever treatment for this devastating condition.